Helsinn

Executive Summary

Helsinn is a fully integrated, global biopharmaceutical company with a 50-year track record, headquartered in Lugano, Switzerland, and incorporated in Ireland. The company specializes in improving the lives of patients with cancer and chronic diseases, with a strong emphasis on supportive care, oncology, and dermato-oncology. Its unique integrated licensing business model allows it to manage products from development through commercialization, leveraging a global commercial presence. With a focus on small molecules, Helsinn has built a diverse portfolio of marketed products and a robust pipeline. The company's history and operational scale position it as a key player in the biopharma industry, particularly in the supportive care segment, where it has established a strong reputation. Looking ahead, Helsinn's growth trajectory is underpinned by its ability to in-license promising assets and advance them through clinical development. The company's deep expertise in oncology and supportive care provides a strategic advantage in a market with high unmet need. While specific pipeline details are limited due to its private status, Helsinn is expected to continue expanding its portfolio through targeted acquisitions and partnerships. Its global commercial infrastructure supports the launch of new products, and the company remains focused on delivering value to patients and stakeholders. With a solid financial foundation and a long-term vision, Helsinn is well-positioned to sustain its growth in the evolving biopharmaceutical landscape.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Clinical Trial Results for Lead Supportive Care Asset75% success
• Q4 2026FDA Approval Decision for Dermato-Oncology Product60% success
• TBDNew Licensing Agreement in Oncology or Supportive Care80% success